Exagen 2024年第四季度GAAP每股收益$(0.20),超出预期的$(0.26),销售额$1365万低于预期的$1385万

财报速递
11 Mar
Exagen (NASDAQ:XGN) 报告季度每股亏损$(0.20),高于分析师一致预期的$(0.26),超出23.08%。与去年同期的每股亏损$(0.31)相比,这是一种35.48%的改善。公司季度销售额为$1365万,低于分析师一致预期的$1385万,差距为1.39%。与去年同期的$1377万销售额相比,这下降了0.80%。

以上内容来自Benzinga Earnings专栏,原文如下:

Exagen (NASDAQ:XGN) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.26) by 23.08 percent. This is a 35.48 percent increase over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $13.65 million which missed the analyst consensus estimate of $13.85 million by 1.39 percent. This is a 0.80 percent decrease over sales of $13.77 million the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10